Low molecular weight nucleoside gelators: a platform for protein aggregation inhibition by Johnson, Litty et al.
Low molecular weight nucleoside gelators: A platform for protein    
aggregation inhibition  
Litty Johnson‡, Maria Galini Faidra Angelerou‡, Bhanu Teja Surikutchi‡, Stephanie Allen‡*, Mischa 
Zelzer ‡* and Maria Marlow‡*  
‡School of Pharmacy, University of Nottingham, Nottingham NG72RD, United Kingdom. 
 
Supporting Information Placeholder
ABSTRACT: Low molecular weight nucleoside gelators hold 
great promise in drug delivery and particularly for the delivery of 
biologics due to their excellent biocompatibility. However, the in-
fluence of these gelators on protein aggregation inhibition has not 
yet been studied. Protein aggregation is the most significant cause 
of protein instability and can severely impact the biological activity 
of the protein, impairing the quality and safety of the formulation. 
Herein, we report the ability of a nucleoside based gelator, N4-oc-
tanoyl-2ʹ-deoxycytidine to inhibit protein aggregation. Using turbi-
dimetric, spectroscopic and microscopic methods, we demonstrate 
that protein aggregation inhibition is dependent on gelator concen-
tration. Moreover, we have found that the protein is still function-
ally active in the hydrogel.  
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Protein and peptide pharmaceuticals are one of the most rapidly 
growing class of clinical therapeutics,1-2 where they have a signifi-
cant therapeutic role in cancer, inflammatory diseases, neurological 
disorders and vaccines.3-4 Despite their importance, the application 
of protein and peptide therapeutics is limited by the propensity of 
these molecules to form aggregates. These aggregates can severely 
impact the biological activity of the peptide/protein, impairing the 
quality and safety of the formulation and hence reducing the effi-
cacy of the therapeutic.5 Hence, a key challenge in the biopharma-
ceutical industry is the development of a stable protein formulation 
that minimizes or prevents protein aggregation.6  
Currently, the main strategy used to inhibit protein aggregation 
is the addition of solute excipients and/or co-solvents (stabilizers) 
such as glycerol7, arginine hydrochloride8, polysorbate 809 and oth-
ers to the protein solution.10 While some compounds such as gly-
cine are  well-known to stabilise antibodies11, they also have the 
drawback of destabilizing other proteins such as  myoglobin. Thus, 
the action of stabilisers often depends on the nature of the target 
protein and hence the choice of an effective stabiliser and selection 
of the stabiliser concentration for a specific protein can be an ex-
haustive process.12-13 In addition, large amounts of stabilizers can 
be required to obtain the desired effect and this may increase the 
cost of the formulation or potentially lead to toxicity.     
Thus, there is an urgent need for the development of novel 
methods to prevent protein aggregation which may be applicable to 
many proteins at low concentrations and which are also relatively 
economic, biocompatible and biodegradable. Hence, herein we de-
scribe for the ability of a supramolecular, low molecular weight 
gelator (LMWG) based hydrogel formulation to prevent protein ag-
gregation. Others in the field have demonstrated the ability of pro-
teins to enhance the order of self-assembled supramolecular hydro-
gels14; prevention of protein denaturisation with these supramolec-
ular hydrogels15 and finally their capability to immobilize proteins 
through interaction with the hydrophobic core of their nanofibers16-
19; however, inhibition of protein aggregation in the presence of a 
supramolecular hydrogel has not yet been reported.          
LMWGs, particularly peptide based molecules, have been eval-
uated as platforms for protein delivery but not as an approach for 
the prevention of protein aggregation.20-21 A peptide based nano-
fibrous hydrogel was found to be effective for delivering HIV DNA 
vaccines.22 Similarly an injectable two layered peptide hydrogel 
system was described as an approach for delivering therapeutic an-
tibodies.23 A novel self-assembling peptide nanofiber hydrogel 
scaffold  was also reported to be used as a carrier system for thera-
peutic proteins with different physical and chemical properties.24   
LMWGs form hydrogels by self-assembly into a cross-linked 
network of nanofibers capable of retaining large amounts of water 
and thus forms a three dimensional structure. Solvophobic forces 
and π-π stacking drives the self-assembly of the gelator and in-
volves the formation of cylindrical nanofibers with a hydrophobic 
core.  These nanofibers in the hydrogel are further stabilized by hy-
drogen bonding.25 Some unique properties of hydrogels such as the 
high water content, soft and porous nature, and biocompatibility 
make them ideal reservoirs for large quantities of water-soluble 
molecules such as peptides and proteins. 26-27 In this study, we have 
used a nucleoside based LMWG, N4-octanoyl-2ʹ-deoxycytidine to 
inhibit aggregation of the proteins lysozyme and beta-lactoglobu-
lin.  
This gelator molecule was previously developed by our group 
as an injectable, self-healing hydrogel.26  The hydrogel system pos-
sesses the ability to shear thin in response to a stress but then re-
forms its structure by the formation of new interactions and hence 
regains its mechanical properties when the stress is removed.28 
Thus the hydrogel can be effectively injected through a syringe but 
then will form a gel. This property makes these hydrogels ideal 
candidates for the delivery of biologics.     
The nucleoside hydrogels were prepared by dissolving low 
quantities (0.3-1.25% w/v) of nucleoside gelator in different buff-
ers with the aid of gentle heating and subsequent cooling to 22 °C. 
The energy barriers for the aqueous dissolution of the gelator is 
overcome by the increased energy supplied by heat. Upon cooling, 
self-assembly into a 3D network of entangled fibers takes place 
 which can entrap water molecules by capillary forces29 and into 
which proteins can be incorporated. This fiber framework of cyti-
dine-based gels was previously shown to control the release of a 
high molecular weight compound, i.e. dextran. 26, 30.        
In this study, we investigated whether protein aggregation 
could be prevented through weak non-covalent interactions be-
tween the protein and the gelator. To investigate this hypothesis we 
chose two model proteins, lysozyme and beta-lactoglobulin, that 
are well known to aggregate under various conditions.31 These 
model proteins at the concentration of 3% w/v were incorporated 
into hydrogels prepared in phosphate buffered saline (pH 7.4) at 37 
°C and then allowed to cool at 22 °C. These hydrogels with lyso-
zyme and beta-lactoglobulin at different concentrations of gelator 
in phosphate buffered saline are shown in ESI, Figure S1.  The 
gelator formed viscoelastic gels stable to vial inversion at physio-
logical pH in the presence of both proteins. The gels were homog-
enously turbid consistent with previous data.26  Oscillatory rheol-
ogy was used to confirm the viscoelastic nature of the protein con-
taining hydrogels (ESI -Figures S9) where the storage and loss 
moduli (Gʹ and Gʹ’)  were similar to previous reported values for 
the gelator without protein at 0.5% w/w (Gʹ = 300 and Gʹʹ’ = 100 
Pa at 1% strain and a frequency of 10 rads-1).26 In addition, the ly-
sozyme in the hydrogel system was found to have the same activity 
as that of the pure lysozyme (ESI, Figure S2).      
 Protein aggregation has been extensively studied and can be 
artificially induced by various triggers such as organic solvents, 
temperature or pH.32 In our study, aggregation was facilitated by 
shifting the solution pH to the protein’s isoelectric point, where the 
charge balance causes attractive forces between proteins to be pre-
dominant.33 We used previously reported  conditions  to induce pro-
tein aggregation i.e. 100 mM   sodium phosphate solution  pH 12.2 
for lysozyme 34 and 1 M sodium chloride  pH 4.6 for beta-lactoglo-
bulin.35  Herein, the two reported conditions for inducing protein 
aggregation in lysozyme and beta-lactoglobulin were successful 
and thus were used subsequently to study the ability of the gelator 
to inhibit protein aggregation. 
 Firstly, we assessed the ability of the nucleoside hydrogels to 
inhibit protein aggregation of lysozyme in sodium phosphate solu-
tion (pH 12.2) with a lysozyme concentration of 3% w/v, where 
lysozyme has been previously reported to aggregate.34  The lyso-
zyme aggregates in the vials were large enough to be visualised by 
the naked eye and could be visually compared with lysozyme in the 
presence of different concentrations of gelator in the same buffer. 
It was observed that in the presence of 0.3% w/v gelator, the aggre-
gation induced turbidity was reduced when compared to lysozyme 
in pH 12.2 solution alone. With increasing gelator concentrations 
(1% and 1.25% w/v), no protein aggregates were visible (Figure 
1A). At pH 12.2, at which protein aggregation is induced, the gela-
tor did not gel as confirmed by vial inversion (ESI, Figure S3C). 
This is likely due to deprotonation of the acidic ribose hydroxyl 
groups which has been reported for nucleosides before 36, convert-
ing the gelator into an ionized state and hence causing it to remain 
in solution. In this condition (solution state) optical observation 
suggests the absence of any aggregates in the presence of gelator.  
The visual observations were confirmed analytically with tur-
bidity measurements. The turbidity of the gelator solutions (con-
trol) and solutions of gelator with lysozyme were measured at 500 
nm as previously reported .37-38 The turbidity of lysozyme is an in-
dicator of protein aggregation as the protein does not exhibit any 
turbidity in physiological pH (ESI, Figure S3D).  The gelator by 
itself showed very low levels of turbidity and hence it did not in-
terfere with the turbidity measurement of aggregates. Indeed, it was 
found that for gelator samples with proteins, increasing gelator con-
centration led to a decrease in the turbidity of the sample. At the 
highest gelator concentration (1.25% w/v), the turbidity of the sam-
ple was found to be nearly zero (Figure 1B).  The decrease in tur-
bidity with increasing concentration of gelator clearly demonstrates 
the inhibition of protein aggregation in the presence of this nucleo-
side gelator. 
The inhibition of lysozyme aggregation in the presence of the 
gelator was further confirmed by optical microscopy. Optical mi-
croscopy was favoured as the lysozyme aggregates were visible to 
the naked eye.  From the microscopy images, it was observed that 
the lysozyme aggregates without any gelator present showed 
densely packed spherical structures (ESI, Figure S4A) measuring 
approximately 5 to 8.8 µm. These amorphous aggregates were 
found to be larger than the aggregates reported by Kumar et al. us-
ing AFM and this is likely due to the higher concentration of pro-
teins (5.5 times more) used here.34 These aggregates were also ob-
served  in the presence of 0.3%, 0.5% and 0.8% w/v gelator alt-
hough their numbers were lower. In contrast, in samples containing 
1% and 1.25% w/v gelator concentrations, these structures were 
absent suggesting that lysozyme does not aggregate under these 
conditions (ESI, Figure S4E and F). 
The ability of the gelator to decrease or inhibit protein aggre-
gation was further explored using an ANS (8-anilino-1-napthalene 
sulfonic acid) binding assay using fluorescence spectroscopy and 
microscopy. Upon protein aggregation, ANS is known to display 
an increase in its fluorescence intensity when bound to  hydropho-
bic regions in the protein that become accessible  upon  aggrega-
tion.34 The fluorescence intensity of the samples and controls were 
recorded at the emission wavelength of 476 nm, 5 hours after addi-
tion of ANS to allow the diffusion of ANS into the solution and its 
interaction with the aggregated protein. Protein samples (P) pre-
pared at pH 12.2 showed increased fluorescence intensity, demon-
strating that the assay is able to report the aggregation of the pro-
tein. A significantly lower fluorescence signal was observed for ly-
sozyme at pH 12.2 in the gelator solution (G) (Figure 2A), con-
sistent with a lower number of ANS binding sites for the fully 
folded proteins in the gelator solution. The significant difference in 
fluorescence intensity was demonstrated  using a one way ANOVA 
followed by post hoc Tukey’s multiple comparison test (P value 
less than 0.0001).  The control samples, of solvent/solution (S) at 
pH 12.2 and 7.4 clearly indicate that the pH of the solution does not 
affect the ANS fluorescence. Further control samples of gels con-
taining no proteins (G) and samples of gelator with preformed pro-
tein aggregates (G+A) confirms the ability of the ANS to detect 
aggregated protein in the gel. This ANS fluorescence data is further 
confirmation of the ability of the gelator to inhibit protein aggrega-
tion.  
Figure 1 A: Photographs of the nucleoside gelator with lyso-
zyme at different gelator concentrations (left to right 0, 0.3, 
0.5, 0.8, 1.0 and 1.25% w/v). B: Turbidity measured at dif-
ferent  gelator concentrations for samples containing gelator 
alone and gelator with 3% w/v lysozyme in 100 mM pH 12.2 
sodium phosphate solution (I = 0.7 M)  after mixing at 37 °C 
and allowing to cool at 22 °C for 15 min. 
 The fluorescence microscopy images of the aggregates (P) 
showed the presence of small fiber-like structures, which were in-
terconnected with each other and spread throughout the sample 
whereas the gelator (1.25% w/v) with lysozyme (G+P) showed the 
absence of these structures. In the control gelator sample (G) these 
structures were also absent (Figure 2B). Further controls of protein 
at pH 7.4 (no fiber–like structures) and preformed aggregated pro-
tein mixed into the gel (presence of fiber-like structures) are shown 
in the ESI Figure S5. These images demonstrate that the gelator 
formulated with the protein showed the absence of fiber like struc-
tures which were evident in the aggregates of protein and this con-
firms inhibition of protein aggregation. However, for these samples 
the gelator is predominantly in solution. Viscosity measurements 
showed shear thinning indicative of worm-like micelles39 (ESI-
Figure S10). Hence, the mechanism of inhibition of protein aggre-
gation is probably the interaction of the amphiphilic gelator mole-
cule with the protein as reported for other amiphiphiles9-10. Hence 
further evidence was required of the ability of the hydrogel fibers 
to inhibit protein aggregation through interaction with their hydro-
phobic core and another protein was selected for this purpose.  
Since the gelator is dissolved at pH 12.2, we selected beta-lactoglo-
bulin, a protein that aggregates at an acidic pH.  
The aggregation of beta-lactoglobulin was studied in 1 M so-
dium chloride as previously reported.35 The pH was initially raised 
to 9 with NaOH and it was finally brought down to pH 4.6 with 
HCl to initiate aggregation. The protein concentration was main-
tained at 3% w/v. Firstly, different solutions of gelator without 
beta-lactoglobulin were prepared at concentrations from 0.15%, 
0.3%, 0.4%, 0.8%, to 1% w/v with the same salt solution (ESI-
Figure S6A and B). All gelator concentrations formed a hydrogel 
stable to vial inversion and it was evident that all gels had a degree 
of heterogeneity where there were regions of turbidity. In addition, 
these regions of turbidity were found to increase with increasing 
gelator concentration. This is considered to be caused by precipita-
tion of gelator which may be due to the pH switch (from pH 9 to 
pH 5) required to induce protein aggregation. The addition of beta-
lactoglobulin was then evaluated at low gelator concentrations 
which displayed the least heterogeneity (ESI, Figure S6 C). These 
samples formed weak gels, particularly at the lowest gelator con-
centration of 0.15% w/v, where water remained at the bottom of the 
inverted vial (ESI, Figure S6 D).       
To investigate protein aggregation in this system, we therefore 
compared turbidity of the hydrogels and the hydrogels with protein 
at the same concentration of gelator. Visually, the 0.15% w/v gel 
with beta-lactoglobulin exhibited more turbidity than the gel with-
out protein whilst for the 0.3% w/v sample, the turbidity was ob-
served to be almost similar (Figure 3A). The turbidity of the gels 
with and without beta-lactoglobulin were then compared quantita-
tively using UV-Vis absorbance at 500 nm. The turbidity data of 
gels without beta-lactoglobulin increased with increasing gelator 
concentration (Figure 3B). The turbidity of 0.15% w/v gelator sam-
ple with beta-lactoglobulin was significantly higher than that of the 
hydrogel without proteins whereas the turbidity of 0.3% w/v hy-
drogel with and without the protein were similar. Protein contain-
ing samples with higher gelator concentrations were not evaluated 
as the hydrogel itself exhibited increasing turbidity values with 
higher gelator concentrations. These turbidity measurements were 
in agreement with the visual observations (ESI-Figure S6A and B). 
To further validate our observations, optical microscopy was 
carried out. However, from these images, it was not possible to 
clearly distinguish between the protein aggregates and the gel struc-
ture as the gel itself exhibited structures similar in appearance to 
that of protein aggregates (ESI, Figure S7).   
The hydrogel’s capability to inhibit protein aggregation was 
further verified by an ANS binding assay and fluorescence micros-
copy in a procedure similar to that described for lysozyme. The re-
sults of ANS fluorescence binding assay revealed a remarkable de-
crease in fluorescence intensity of the hydrogel containing beta-
lactoglobulin (G+P) when compared to the solutions of protein (P) 
only in the same conditions (Figure 4A). It was also evident that 
neither the pH nor the presence of the gel induced ANS fluores-
cence as no significant fluorescence intensity was detected in the 
gel alone or the solvent itself. The fluorescence microscopy images 
of the protein in the presence of hydrogel (G+P) did not exhibit any 
fiber-like interconnected structures such as those observed for the 
aggregated protein (P) (Figure 4B). Further controls of protein at 
pH 7.4 (no fiber –like structures) and preformed aggregated protein 
mixed into the gel (presence of fiber-like structures) are shown in 
Figure 2 A: ANS Fluorescence intensities of samples and 
controls of lysozyme (solvent(S), gelator (G), gelator with 
protein (G+P), protein (P), gelator with aggregates (G+A) at 
pH 12.2 (aggregation inducing) and pH 7.4 (non-aggregation 
inducing), excited at 370 nm and emission measured at 476 
nm after 5 hours. B: Fluorescence microscopy images of ly-
sozyme (P), gelator solution (G) and gelator with lysozyme 
(G+P) at pH 12.2. * indicates significant difference with P-
value of 0.0001 by one way ANOVA followed by post hoc 
Tukey’s multiple comparison test 
Figure 3 A: Photograph of nucleoside gelator with beta-lac-
toglobulin showing the intensity of cloudiness. Gelator con-
centration from left to right 0, 0.15 and 0.3% w/v. B: Plot of 
gelator concentration versus turbidity for gelator alone and 
gelator with 3% w/v beta-lactoglobulin in 1 M NaCl at pH 
4.6 (I = 2 M) at different gelator concentrations after mixing 
at 37 °C and allowing to cool at 22 °C for 15 min. 
 ESI Figure S8. These data further proves our hypothesis that the 
gelator has the strong ability to inhibit protein aggregation. A pos-
tulation of the mechanism of inhibition of protein aggregation will 
now be discussed. 
Since recent data from our group reports that a large amount of 
the gelator is in the fiber network compared to a small proportion 
in solution25, there is probably a significant contribution from im-
mobilisation of the protein by the gel fiber network17-18 and a 
smaller contribution from the amiphiphilic gelator in solution. In 
general, supramolecular gels are well established as nanofiber 3D 
frameworks with a hydrophobic core and solvent filled cavities40 
that can be used to immobilise molecules in processes such as 
crystillisation.41-42        
 Based on our experimental results we have shown that a supra-
molecular low molecular weight 2ʹ-deoxycytidine based gelator ex-
hibits the ability to suppress the aggregation of proteins with a 
broad range of isoelectric points (alkaline and acidic). To our 
knowledge, this is the first report of using a low molecular weight 
gelator for the inhibition of protein aggregation. Thus, the novel 2ʹ-
deoxycytidine based hydrogel has the potential to contribute to 
tackling one of the most important challenges in formulation of bi-
ologics, to prevent protein aggregation and improve the therapeutic 
efficacy of biotherapeutics.43  
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